Cohance Invests Rs 23 Crore In Oligonucleotide Building Block Manufacturing Facility in Hyderabad
12 Aug 2025 11:14 PM IST12 Aug 2025 11:14 PM IST
Cohance Lifesciences, active in pharma, specialty chemicals and formulations, said it invested Rs 23 crore on its new cGMP oligonucleotide building block manufacturing facility in Hyderabad, according to a release.
Cohance Lifesciences (Image:DC)
Hyderabad: Cohance Lifesciences, active in pharma, specialty chemicals and formulations, said it invested Rs 23 crore on its new cGMP oligonucleotide building block manufacturing facility in Hyderabad, according to a release.
The new facility will enable the company to take high-value chemistries from laboratory scale to commercial manufacturing. Integrated with a pilot plant for early-stage synthesis and for non-GMP scale-up, the facility will add fit-for-purpose GMP capacity of up to 700 kg annually, with room for future expansion.
“Oligonucleotides are a fast-emerging therapeutic class, and innovators are seeking integrated, cost-efficient partners with scalable GMP capacity. This facility complements our pilot and scale-up assets, positioning Cohance to deliver with speed, quality, and flexibility,” said Vivek Sharma, executive chairman, Cohance Lifesciences.
“Oligonucleotides are a fast-emerging therapeutic class, and innovators are seeking integrated, cost-efficient partners with scalable GMP capacity. This facility complements our pilot and scale-up assets, positioning Cohance to deliver with speed, quality, and flexibility,” said Vivek Sharma, executive chairman, Cohance Lifesciences.
( Source : Deccan Chronicle )
Next Story